For laboratory research use only. Not for human consumption. Not for clinical or therapeutic use. Not evaluated by the FDA.
For laboratory research use only. Not for human consumption. Not for clinical or therapeutic use. Not evaluated by the FDA.
Before You Checkout
Bundle complementary compounds together — priced below buying each separately.
Recovery Stack
Tissue repair & regeneration research
Growth Axis Stack
Growth-hormone-axis research
Longevity Stack
Cellular & metabolic longevity
A synthetic dual-agonist peptide investigated for its binding interactions at the GIP and GLP-1 receptor systems. Used exclusively in preclinical in-vitro research settings to study incretin receptor pharmacodynamics, downstream cAMP signaling, and glucose-metabolism pathways in cell and animal model studies.
Dosage
10mg
Form
Lyophilized Powder
Bundle & Save
$39.95
Quantity
Research Application Guidelines
This research compound is designed exclusively for controlled in vitro studies carried out by trained professionals. It is not intended for human or animal use and must not be incorporated into foods, cosmetics, medications, or diagnostic processes.
Regulatory Notice
This material has not been evaluated by the FDA and is not sold for the purpose of diagnosing, treating, curing, or preventing any condition. All handling, storage, and research use must comply with applicable regulations and institutional requirements.
Purchase & Responsibility Agreement
By purchasing from Ascension Labs, the buyer confirms that they are a qualified researcher or authorized laboratory. All sales are final. The buyer assumes full responsibility for the proper handling, storage, usage, and regulatory compliance of this material.
What's Included
Storage Guidelines
Quality Assurance
Disclaimer: Our peptides are research-grade products for laboratory use only. They are not approved for human consumption or medical use. Always follow proper laboratory safety protocols.
Tirzepatide is a synthetic dual agonist of the GIP and GLP-1 incretin receptors. It is studied in vitro for dual-incretin receptor binding, downstream cAMP signaling, and glucose-metabolism pathway characterization.
Also referred to as: Tirzepatide acetate, GIP/GLP-1 dual agonist, dual incretin agonist, LY3298176.
Tirzepatide is investigated as a synthetic dual agonist that simultaneously engages the GIP and GLP-1 incretin receptors. In cell-based assays, binding at both class B GPCRs is coupled to intracellular cAMP generation, and researchers characterize its biased signaling and relative receptor potency to understand how a single molecule activates two incretin pathways under controlled conditions.
Tirzepatide, also designated LY3298176, is a synthetic 39-amino-acid peptide built on a modified GIP backbone. It carries a C20 fatty diacid moiety attached via a linker, which supports albumin binding and extended stability. This structural class places it among lipidated incretin-mimetic peptides studied for their multi-receptor binding characteristics in laboratory pharmacology.
Single GLP-1 receptor agonists bind only GLP-1R. In comparative binding studies, tirzepatide additionally engages the GIP receptor, making it a dual-incretin ligand. Researchers examine this by measuring cAMP responses at each receptor separately, where tirzepatide shows measurable activity at both sites, unlike mono-agonists that remain silent at the GIP receptor.
Yes. Every batch of Tirzepatide is independently tested by HPLC and mass spectrometry, and ships with a lot-specific Certificate of Analysis verifying 99.2% purity and molecular identity.
Store lyophilized Tirzepatide at -20°C for long-term storage or 2-8°C short-term. After reconstitution, keep refrigerated at 2-8°C and avoid repeated freeze-thaw cycles.
No. Tirzepatide is sold strictly for in-vitro research and laboratory use only. It is not a drug or supplement and is not intended for human or animal consumption.